导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.32% | 2333/4773 |
| 近一周 | -0.71% | 1205/5465 |
| 近一月 | -3.83% | 2832/5421 |
| 近一季 | -10.55% | 3775/5231 |
| 近半年 | -7.34% | 3322/4920 |
| 近一年 | 4.49% | 1849/4394 |
| 近两年 | 56.25% | 1333/2954 |
| 近三年 | 31.63% | 1031/2253 |
| 成立以来 | 287.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.68% 1220/4961 |
15.32% 1682/5312 |
- - |
- - |
| 2025 | 28.23% 1500/4813 |
1.08% 1708/3635 |
2.28% 1685/4076 |
22.75% 1619/4524 |
1.05% 1569/4813 |
| 2024 | 5.42% 1836/3463 |
-0.09% 1074/2808 |
-3.35% 1353/3014 |
11.53% 2506/3129 |
-2.11% 1960/3463 |
| 2023 | -2.08% 555/2656 |
7.72% 527/2280 |
-2.75% 648/2385 |
-3.97% 1026/2515 |
-2.66% 508/2655 |
| 2022 | -16.09% 449/2207 |
-9.81% 350/1919 |
4.17% 1048/2016 |
-11.80% 590/2113 |
1.26% 1319/2208 |
| 2021 | 17.12% 246/1822 |
0.77% 278/1255 |
10.23% 485/1330 |
5.15% 290/1466 |
0.27% 1146/1822 |
| 2020 | 29.23% 543/1250 |
-1.64% 227/1028 |
17.24% 382/1067 |
7.68% 766/1164 |
4.06% 873/1184 |
| 2019 | 31.41% 470/1092 |
31.23% 211/754 |
-8.87% 614/804 |
2.78% 284/850 |
6.90% 526/918 |
| 2018 | -27.92% 429/834 |
- - |
- - |
- - |
-12.93% 495/691 |
| 2017 | 9.21% 309/714 |
- - |
- - |
- - |
- - |
| 2016 | -6.16% 194/605 |
- - |
- - |
- - |
- - |
| 2015 | 47.03% 25/575 |
- - |
- - |
- - |
- - |
| 2014 | 38.71% 132/237 |
- - |
- - |
- - |
- - |
| 2013 | 16.61% 20/186 |
- - |
- - |
- - |
- - |
| 2012 | 7.77% 63/140 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证500指数增强(LOF)A VS. 长安沪深300非周期A(740101) |